04:43 PM EDT, 07/07/2025 (MT Newswires) -- Biogen (BIIB) said late Monday its Q2 GAAP and adjusted earnings could be impacted by $0.26 per diluted share due to a $46 million charge from acquired in-process research and development, as well as upfront and milestone expenses.
Biogen shares rose 1.3% during after-hours trading.